UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005623
Receipt number R000006635
Scientific Title Randomized study comparing the efficacy of aprepitant with palonosetron as antiemetic drug during chemotherapy including cisplatin
Date of disclosure of the study information 2011/05/20
Last modified on 2020/10/30 21:43:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized study comparing the efficacy of aprepitant with palonosetron as antiemetic drug during chemotherapy including cisplatin

Acronym

KDOG 1002

Scientific Title

Randomized study comparing the efficacy of aprepitant with palonosetron as antiemetic drug during chemotherapy including cisplatin

Scientific Title:Acronym

KDOG 1002

Region

Japan


Condition

Condition

advanced or recurrent esophageal or gastric carcinoma

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To assess the efficacy and safety of aprepitant versus palonosetron for chemotherapy-induced nausea and vomiting

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

complete response (no emesis and no rescue therapy) within 120 hours after the start of the first course of chemotherapy

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

aprepitant

Interventions/Control_2

palonosetron

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1. Patient with advanced or recurrent esophageal or gastric carcinoma
2. Chemotherapy including cisplatin 60 mg/m2 or more is planned
3. Chemotherapy-naive patient
4. Two courses or more of chemotherapy is planned

Key exclusion criteria

1. Serious heart disease, serious renal disease, serious liver disease, and poor controlled Diabetes
2. Woman during the pregnancy or with the possibility of the pregnancy
3. Patient with severe mental disorder
4. The allergic past history for the serotonin receptor antagonist
5. Patient with nausea, vomiting due to brain tumor or ileus
6. Patient who plans to receive radiotherapy for the chest, abdomen, or pelvis
7. Patient using antiemetic drug within 48 hours before chemotherapy
8.Patients who are judged inappropriate for the entry into this study by the investigator

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Wasaburo
Middle name
Last name Koizumi

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology

Zip code

252-0374

Address

1-15-1, Kitazato, Sagamihara, Kanagawa, Japan

TEL

042-778-8111

Email

k.ishido@kitasato-u.ac.jp


Public contact

Name of contact person

1st name Kenji
Middle name
Last name Ishido

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology

Zip code

252-0374

Address

1-15-1, Kitazato, Sagamihara, Kanagawa, Japan

TEL

042-778-8111

Homepage URL


Email

k.ishido@kitasato-u.ac.jp


Sponsor or person

Institute

Kitasato University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Kitasato University School of Medicine, Department of Gastroenterology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kitasato University Medical Ethics Organization

Address

1-15-1 Kitasato, Minami-ku

Tel

+81427788111

Email

rinrib@med.kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 05 Month 20 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/27254283/

Publication of results

Published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/27254283/

Number of participants that the trial has enrolled

85

Results

The primary endpoint of complete response was not achieved, but AGD seems to be more effective than PD for the prevention of HEC-induced vomiting.

Results date posted

2020 Year 10 Month 30 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

From November 2010 through August 2013, a total of 85 patients were enrolled in the study

Participant flow

One patient in the PD group suddenly died on day 5 of the first treatment cycle and was therefore excluded from the efficacy analysis. Effectiveness and safety were evaluated in the remaining 84 patients

Adverse events

none

Outcome measures

The complete response rate during the overall study period, the primary endpoint, was 67.4% in the AGD group and 58.5% in the PD group. This difference was not significant (p = 0.399).

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 10 Month 08 Day

Date of IRB

2010 Year 10 Month 01 Day

Anticipated trial start date

2010 Year 10 Month 01 Day

Last follow-up date

2015 Year 03 Month 31 Day

Date of closure to data entry

2015 Year 05 Month 31 Day

Date trial data considered complete

2015 Year 05 Month 31 Day

Date analysis concluded

2016 Year 10 Month 30 Day


Other

Other related information



Management information

Registered date

2011 Year 05 Month 20 Day

Last modified on

2020 Year 10 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006635


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name